AngioDynamics, Inc.
AngioDynamics delivered another strong quarter, demonstrating sustained top-line growth and expanding profitability driven by robust performance in Med Tech and thrombectomy portfolios. The company continues to execute on strategic priorities, raising full-year guidance for the third consecutive quarter.
Key takeaways
- Med Tech segment, led by Auryon, achieved 19th consecutive quarter of double-digit YoY growth, supported by international expansion post-CE Mark.
- Thrombectomy portfolio (AlphaVac and AngioVac) grew approximately 18% YoY, with AlphaVac showing record sequential revenue increase and positive clinical adoption.
- NanoKnife saw notable growth in disposables and capital, with expanded European indications and a favorable CMS CPT 1 code rollout bolstering market access.
- The company reaffirmed its strategic focus on large, high-margin markets amid macro uncertainties, leveraging innovation and clinical milestones.
- Full-year revenue and EBITDA guidance were raised for the third straight quarter, reflecting confidence in continued profitable growth.